Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741 is registered in ClinicalTrials.gov with Gregory Daniels as lead sponsor.

NCT NCT03991741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Lead sponsor
Gregory Daniels
Phase
Phase 1
Overall status
Terminated
Start date
October 7, 2020
Completion date
January 26, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced refractory/recurrent head and neck cancer, locally advanced refractory/recurrent melanoma, metastatic head and neck cancer, metastatic melanoma